Some freshly-adopted regulatory moves are expected to facilitate more advantageous prerequisites for Vietnamese state-owned enterprises to pick up their divestment pace, and thus enrich the domestic stock market with foreign capital inflows.
Targets being tweaked by prepared pharma 20:53 | 09/06/2021
illustration photo. Source: freepik.com
According to financial statements from Vietnamese pharma titans like DHG Pharmaceutical JSC, Traphaco JSC, and Imexpharm Pharmaceutical JSC (IMP), there were strong rises in both revenues and profit in the first months of 2021.
DHG, the biggest publicly-traded drugmaker, made consolidated revenue of $50 million, up from just over $40 million in the same period last year. Consolidated after-tax profit hit $8.87 million, up 15.24 per cent on-year.
Similarly, Traphaco, the countryâs second-largest publicly-traded drugmaker, saw on-year rises of 20.87 per cent and 34.06 per cent in consolidated revenue and consolidated after-tax profit respectively during the period. IMP, Vietnamâs fourth-biggest, witnessed a 23.1 per cent on-year increase in before-tax profit in the first four months, while its net revenue rose 9 per cent.
Monde Nissin Corporation, which raised the largest initial public offering (IPO) in Philippine capital markets’ history amounting to 48.6 billion pesos (US$1.02 billion), had a lukewarm trading debut on June 1, closing at 13.48 pesos per share, compared with its offer price of 13.50 pesos each.
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.NOT FOR PUBLICATION OR DISTRIBUTION IN THE .